Narumi Mizuno

Specialty Clinical Development Dept.
Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
Tokyo, Tokyo, Japan

Presentation(s):

• OC 06.3 - Final Analysis Results from a Phase III Study of Emicizumab Prophylaxis for Acquired Hemophilia A (AGEHA)

  Saturday, June 24, 2023
  13:30 – 13:45 ET